Jiahui Cancer Center begins CAR-T therapy for first international patient with solid tumors

Jiahui International Cancer Center in Shanghai has initiated treatment with Satri-cel, the world's first approved CAR-T therapy for solid tumors, on an international patient. This marks a significant milestone, as Satri-cel is the first chimeric antigen receptor (CAR)-T cell therapy authorized for the treatment of solid malignancies.

The patient, who is from outside China, received the therapy at the center, highlighting Jiahui's growing international reach in advanced cancer treatment. This development is particularly important as CAR-T therapies have traditionally been focused on blood cancers, and this marks an expansion into solid tumor applications.

Jiahui International Cancer Center aims to provide leading-edge cancer care, and the adoption of Satri-cel aligns with this mission. The center is leveraging this new treatment modality to offer advanced options for patients with specific types of solid tumors that may not respond to conventional therapies.

The introduction of Satri-cel underscores the potential of personalized immunotherapies in oncology. By reprogramming a patient's own T-cells, the therapy aims to target and eliminate cancer cells more effectively, offering new hope for those with previously difficult-to-treat conditions.